Enanta Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Enanta Pharmaceuticals

12/05/2025 21:43

Enanta Pharmaceuticals Inc ENTA.OQ reported a quarterly adjusted loss of $1.06​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-1.47.  The mean expectation of five analysts for the quarter was for a loss of $1.14 per share. Wall Street expected results to range from $-1.42 to -98 cents per share.

Revenue fell 12.5% to $14.93 million from a year ago; analysts expected $15.95 million.

Enanta Pharmaceuticals Inc's reported EPS for the quarter was a loss of $1.06​.

The company reported a quarterly loss of $22.64 million.

Enanta Pharmaceuticals Inc shares had fallen by 4.5% this quarter and lost 8.3% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 12.9% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Enanta Pharmaceuticals Inc is $19.00

This summary was machine generated from LSEG data May 12 at 08:43 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-1.14
-1.06
Beat
Dec. 31 2024
-1.35
-1.05
Beat
Sep. 30 2024
-1.16
-1.36
Missed
Jun. 30 2024
-1.45
-1.07
Beat